Quantitative measurement of cartilage morphology in osteoarthritis: current knowledge and future directions
- PMID: 36380243
- PMCID: PMC10509082
- DOI: 10.1007/s00256-022-04228-w
Quantitative measurement of cartilage morphology in osteoarthritis: current knowledge and future directions
Abstract
Quantitative measures of cartilage morphology ("cartilage morphometry") extracted from high resolution 3D magnetic resonance imaging (MRI) sequences have been shown to be sensitive to osteoarthritis (OA)-related change and also to treatment interventions. Cartilage morphometry is therefore nowadays widely used as outcome measure for observational studies and randomized interventional clinical trials. The objective of this narrative review is to summarize the current status of cartilage morphometry in OA research, to provide insights into aspects relevant for the design of future studies and clinical trials, and to give an outlook on future developments. It covers the aspects related to the acquisition of MRIs suitable for cartilage morphometry, the analysis techniques needed for deriving quantitative measures from the MRIs, the quality assurance required for providing reliable cartilage measures, and the appropriate participant recruitment criteria for the enrichment of study cohorts with knees likely to show structural progression. Finally, it provides an overview over recent clinical trials that relied on cartilage morphometry as a structural outcome measure for evaluating the efficacy of disease-modifying OA drugs (DMOAD).
Keywords: Cartilage loss; Knee; MRI; Osteoarthritis.
© 2022. The Author(s).
Conflict of interest statement
Wolfgang Wirth: employee and shareholder of Chondrometrics GmbH. Susanne Maschek: employee and shareholder of Chondrometrics GmbH. Anna Wisser: employee of Chondrometrics GmbH. Felix Eckstein: CEO and shareholder of Chondrometrics GmbH and received personal fees from AbbVie, Galapagos NV, HealthLink, ICM, IRIS, Kolon TissueGene, Merck KGaA, Novartis, Roche and Samumed and grants from Foundation for the NIH, University of California, San Francisco, NIH/National Heart, Lung, and Blood Institute, Bioclinica, Galapagos NV, Novartis, TissueGene, Erlangen University Hospital, University of Sydney, CALIBR, University of Basel, University of Western Ontario, Stanford University, ICM Co., Ltd., UMC Utrecht, Federal Ministry of Education and Research, Germany. Christoph Ladel received personal fees from LinkHealth Wengzhou, ReumaNederland Amsterdam, UMC Utrecht, Charité Hospital Berlin. Frank Roemer: shareholder of Boston Imaging Core Lab. (BICL), LLC. He is consultant to Calibr and Grünenthal.
Figures



References
-
- Vos T, Abajobir AA, Abbafati C, et al. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–1259. doi: 10.1016/S0140-6736(17)32154-2. - DOI - PMC - PubMed
-
- Prieto-Alhambra D, Judge A, Javaid MK, Cooper C, Diez-Perez A, Arden NK. Incidence and risk factors for clinically diagnosed knee, hip and hand osteoarthritis: influences of age, gender and osteoarthritis affecting other joints. Ann Rheum Dis. 2014;73(9):1659–64. doi: 10.1136/annrheumdis-2013-203355. - DOI - PMC - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources